Literature DB >> 26284715

Costs Associated With Using Different Insulin Preparations.

Tracy Tylee1, Irl B Hirsch1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26284715     DOI: 10.1001/jama.2015.7032

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

Review 1.  Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.

Authors:  Guillermo Umpierrez; Mary Korytkowski
Journal:  Nat Rev Endocrinol       Date:  2016-02-19       Impact factor: 43.330

Review 2.  Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.

Authors:  David Beran; Margaret Ewen; Kasia Lipska; Irl B Hirsch; John S Yudkin
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

3.  If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?).

Authors:  Alan W Carter; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2016-11-01

4.  Regular Insulin Administered With the V-Go Disposable Insulin Delivery Device in a Clinical Diabetes Setting: A Retrospective Analysis of Efficacy and Cost.

Authors:  David Sutton; Charissa Higdon; Mark Carmon; Scott Abbott
Journal:  Clin Diabetes       Date:  2016-10

5.  All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.

Authors:  Arto Y Strandberg; Fabian J Hoti; Timo E Strandberg; Solomon Christopher; Jari Haukka; Pasi Korhonen
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

6.  Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.

Authors:  Samaneh Kabul; Robert C Hood; Ran Duan; Amy M DeLozier; Julie Settles
Journal:  Health Qual Life Outcomes       Date:  2016-09-30       Impact factor: 3.186

7.  Non-peptidyl small molecule, adenosine, 5'-Se-methyl-5'-seleno-, 2',3'-diacetate, activates insulin receptor and attenuates hyperglycemia in type 2 diabetic Leprdb/db mice.

Authors:  Zi-Jian Lan; Zhenmin Lei; Alexandros Yiannikouris; Thirupathi Reddy Yerramreddy; Xian Li; Hayley Kincaid; Katie Eastridge; Hannah Gadberry; Chloe Power; Rijin Xiao; Lei Lei; Olivia Seale; Karl Dawson; Ronan Power
Journal:  Cell Mol Life Sci       Date:  2019-08-05       Impact factor: 9.261

8.  Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes.

Authors:  Pablo F Mora; David R Sutton; Ashwini Gore; Bantwal Baliga; Rebecca F Goldfaden; Carla Nikkel; John Sink Ii; Beverley Adams-Huet
Journal:  BMJ Open Diabetes Res Care       Date:  2020-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.